InMed's Senior VP, Preclinical Research and Development, Dr. Eric Hsu, join the Benzinga Small Cap Conference Panel Discussion "Pharmaceutical Cannabinoids and their Impact on Treatments...

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids....

InMed CEO, Eric A. Adams, and Shadd Dales of The Dales Report talk about the progress of InMed’s pharmaceutical programs and expanding its markets with...

In a discussion with The Dales Report, InMed’s CEO, Eric A. Adams, discusses the BayMedica acquisition and the market opportunity of new high-value, rare cannabinoids...

Shadd Dales of The Dales Report asks InMed CEO, Eric A. Adams, about the growing interest in the pharmaceutical development of non-intoxicating cannabinoids. Read the...

How will InMed’s acquisition of BayMedica strengthen InMed’s pharmaceutical programs? InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, to explain...